India is about to test a radical idea: can a country known as the world’s pharmacy also become its slimming clinic? The imminent arrival of low-cost versions of semaglutide ~ marketed globally as Wegovy and Ozempic by Novo Nordisk ~ could turn a once-exclusive therapy into a mass-consumption drug. In India, where price determines access more than innovation, this shift is tectonic. Consider the scale. India already carries one of the world’s heaviest burdens of metabolic disease, with tens of millions living with type-2 diabetes and many more on the edge of it.

Until now, effective weight-loss drugs existed, but largely as aspirational medicine ~ prescribed sparingly, often abandoned early due to cost. That barrier is about to fall. Indian pharmaceutical giants are preparing to flood the market with competing versions. If pricing behaves as it typically does in India’s generics ecosystem, monthly treatment cost could drop to a fraction of current levels. That would place a powerful metabolic drug within reach of the middle class. The consequences will not be confined to India. When Indian manufacturers scale production, global pricing shifts.

This is not conjecture; it is precedent. The transformation of HIV treatment in the early 2000s ~ driven by Indian generics and endorsed by institutions like the World Health Organisation ~ turned life-saving drugs from Western monopolies into global public goods. A similar dynamic could now emerge in obesity treatment, especially across Africa, Southeast Asia and Latin America. But there is a difference. HIV drugs treated a fatal disease. Semaglutide treats a condition that straddles medicine and lifestyle. That ambiguity will define India’s challenge. Already, the contours of misuse are visible. In cities like Mumbai and Delhi, weight-loss injections are drifting beyond endocrinology clinics into gyms, beauty centres, and online consultations. The risk is not merely medical ~ though side effects from improper dosing are real ~ but cultural.

A drug designed for disease management is being reimagined as a shortcut to aesthetic transformation. The Central Drugs Standard Control Organisation will therefore face a dual burden: ensuring manufacturing quality in a crowded generics market, and enforcing prescription discipline in an environment prone to commercial excess. Neither task is trivial in a healthcare system that remains unevenly regulated. There is also a deeper economic tension. If India succeeds, it could unlock a multibillion-dollar export market and reinforce its position as the backbone of global generics.

If it fails ~ through substandard production or misuse ~ it risks discrediting an entire therapeutic class. The promise of semaglutide is undeniable. It offers, for the first time, a pharmacological lever against a condition long resistant to intervention. But its power lies not in rapid weight loss, as social media would have it, but in sustained metabolic control. India’s real test, then, is not whether it can make these drugs cheap. It is whether it can make their use disciplined. In that distinction lies the difference between a public health breakthrough and a pharmaceutical free-for-all.

Markets remain steady amid West Asia tensions; risks rise if Hormuz disruptions persist: Jefferies Report

The report noted that markets have shown surprising resilience despite intensifying geopolitical tensions in the Middle East, stating that investors have largely held steady even amid “historic news flow” from the region.

India’s maritime dilemma in the Strait of Hormuz has exposed a familiar but uncomfortable truth: in geopolitics, principle often yields to necessity

US court divorce on ‘irretrievable breakdown’ not enforceable in India; SC grants relief under Article 142

The Supreme Court has held that a divorce decree granted by a United States court on the ground of irretrievable breakdown of marriage is not enforceable in India where the parties are governed by the Hindu Marriage Act, which does not recognise such a ground.

You might be interested in

Return of the Raj: Black Day for Indian press freedom as UNI journos booted out of office

Return of the Raj: Black Day for Indian press freedom as UNI journos booted out of office

UNI office at Rafi Marg sealed; staff call action ‘attack on press freedom’

UNI office at Rafi Marg sealed; staff call action ‘attack on press freedom’

US-Israel-Iran Live Updates: Trump rejects ceasefire, presses allies on Hormuz; Iran warns of wider retaliation

US-Israel-Iran Live Updates: Trump rejects ceasefire, presses allies on Hormuz; Iran warns of wider retaliation

© The Statesman